List of bibliographic references indexed by Années de vie ajustées sur la qualité
Number of relevant bibliographic references: 12.
| Ident. | Authors (with country if any) | Title |
|---|
| 000E15 (2019) |
Saara Huoponen [Finlande] ; Kalle J. Aaltonen [Finlande] ; Jaana Viikinkoski [Finlande] ; Jarno Rutanen [Finlande] ; Heikki Relas [Finlande] ; Kirsi Taimen [Finlande] ; Kari Puolakka [Finlande] ; Dan Nordström [Finlande] ; Marja Blom [Finlande] | Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis |
| 001210 (2018) |
I Igo Bermejo [Royaume-Uni] ; Shijie Ren [Royaume-Uni] ; Emma Simpson [Royaume-Uni] ; Mark Clowes [Royaume-Uni] ; David L. Scott [Royaume-Uni] ; Adam Young [Royaume-Uni] ; Matt Stevenson [Royaume-Uni] | Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. |
| 001859 (2017) |
Jeroen P. Jansen [États-Unis] ; Devin Incerti [États-Unis] ; Alex Mutebi [États-Unis] ; Desi Peneva [États-Unis] ; Joanna P. Macewan [États-Unis] ; Bradley Stolshek [États-Unis] ; Primal Kaur [États-Unis] ; Mahdi Gharaibeh [États-Unis] ; Vibeke Strand [États-Unis] | Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. |
| 001873 (2017) |
I Igo Bermejo [Royaume-Uni] ; Matt Stevenson [Royaume-Uni] ; Rachel Archer [Royaume-Uni] ; John W. Stevens [Royaume-Uni] ; Edward Goka [Royaume-Uni] ; Mark Clowes [Royaume-Uni] ; David L. Scott [Royaume-Uni] ; Adam Young [Royaume-Uni] | Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. |
| 001B83 (2016) |
Anders Gülfe [Suède] ; Johan K. Wallman [Suède] ; Lars Erik Kristensen [Danemark] | EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden. |
| 001C81 (2016) |
Matt Stevenson [Royaume-Uni] ; Rachel Archer [Royaume-Uni] ; Jon Tosh [Royaume-Uni] ; Emma Simpson [Royaume-Uni] ; Emma Everson-Hock [Royaume-Uni] ; John Stevens [Royaume-Uni] ; Monica Hernandez-Alava [Royaume-Uni] ; Suzy Paisley [Royaume-Uni] ; Kath Dickinson [Royaume-Uni] ; David Scott [Royaume-Uni] ; Adam Young [Royaume-Uni] ; Allan Wailoo [Royaume-Uni] | Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. |
| 002072 (2015) |
Kostas Athanasakis [Grèce] ; Filippos Tarantilis ; Konstantina Tsalapati ; Thomais Konstantopoulou ; Eleni Vritzali ; John Kyriopoulos | Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece. |
| 002073 (2015) |
Eiichi Tanaka [Japon] ; Eisuke Inoue ; Daisuke Hoshi ; Yoko Shimizu ; Akiko Kobayashi ; Naoki Sugimoto ; Kumi Shidara ; Eri Sato ; Yohei Seto ; Ayako Nakajima ; Shigeki Momohara ; Atsuo Taniguchi ; Hisashi Yamanaka | Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. |
| 002074 (2015) |
Maria K. Kvamme [Norvège] ; Elisabeth Lie [Norvège] ; Till Uhlig [Norvège] ; Tron A. Moger [Norvège] ; Tore K. Kvien [Norvège] ; Ivar S. Kristiansen [Norvège] | Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies. |
| 003519 (2012) |
Alexander Diamantopoulos [Royaume-Uni] ; Maurizio Benucci ; Stefano Capri ; Wolfgang Berger ; Neil Wintfeld ; Giovanni Giuliani ; Walter Ricciardi | Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. |
| 003859 (2011) |
A A Baranov ; E I Alekseeva ; S I Valieva ; T M Bzarova ; R V Denisova ; A O Lisitsyn ; E G Chistiakova ; T V Sleptsova ; E V Mitenko | [Biological therapy in pediatric rheumatology]. |
| 004314 (????) |
Sergio Iannazzo [Italie] ; Maurizio Benucci [Italie] ; Ennio Giulio Favalli [Italie] | Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting. |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdFr.i -k "Années de vie ajustées sur la qualité"
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdFr.i \
-Sk "Années de vie ajustées sur la qualité" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= indexItem
|index= KwdFr.i
|clé= Années de vie ajustées sur la qualité
}}
| This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021 |  |
